Paclitaxel, ifosfamide and cisplatin (TIP) in patients (pts) with poor prognosis nonseminomatous germ cell tumor (NSGCT) with unfavourable serum tumor markers (STM) decline: A phase II study

被引：0
|
作者：
Israelyan, E. R. [1 ]
Tryakin, A. [2 ]
Rumyantsev, A. [1 ]
Fedyanin, M. [3 ]
Tyulyandina, A. [1 ]
Klimov, A. [4 ]
Matveev, V. [5 ]
Volkova, M. I. [6 ]
Paychadze, A. [7 ]
Bychkov, Y. [8 ,9 ]
Yunaev, G. [10 ]
Tsareva, A. [1 ]
Tikhomirova, T. [1 ]
Zorinova, A. [1 ]
Tjulandin, S. [11 ]
机构：
[1] Natl Med Res Ctr Oncol, Chemotherapy Dept 4, Moscow, Russia
[2] Natl Med Res Ctr Oncol, Clin Pharmacol & Chemotherapy Dept, Moscow, Russia
[3] Moscow Dept Hlth, Chemotherapy Dept, Moscow Multidisciplinary Clin Ctr Kommunarka, Moscow, Russia
[4] Natl Med Res Ctr Oncol, Oncourol Dept, Moscow, Russia
[5] NN Blokhin Natl Med Res Ctr Oncol, Oncourol Dept, Moscow, Russia
[6] City Clin Hosp, Moscow Healthcare Dept, Genitourinary Oncol Dept, Oncol Ctr 1, Moscow, Russia
[7] PA Hertsen Moscow Oncol Res Inst, Chemotherapy Dept, Moscow, Russia
[8] Russian Ctr Rentgenoradiol, Chemotherapy Dept, Moscow, Russia
[9] Moscow Res Inst Diagnost & Surg, Chemotherapy Dept, Moscow, Russia
[10] Natl Med Res Ctr Oncol, Intens Care Dept, Moscow, Russia
[11] Natl Med Res Ctr Oncol, Chemotherapy Dept 22, Moscow, Russia
来源：
ANNALS OF ONCOLOGY | 2024年 / 35卷
关键词：
D O I：
10.1016/j.annonc.2024.08.770
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
707P
引用
收藏
页码：S543 / S543
页数：1
相关论文
共 50 条
  • [1] Paclitaxel (P) and cisplatin (C) as salvage treatment for nonseminomatous germ cell tumor (NSGCT) patients (pts)
    Tjulandin, S
    Titov, D
    Breder, V
    Sidorova, N
    Popov, A
    Garin, A
    EUROPEAN JOURNAL OF CANCER, 1997, 33 : 168 - 168
  • [2] Outpatient administration of paclitaxel, ifosfamide, and cisplatin (TIP) for germ cell tumor
    Schepers, Allison J.
    Smith, David C.
    McDevitt, Rachel L.
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2023, 29 (04) : 912 - 916
  • [3] Paclitaxel, Ifosfamide, and Cisplatin in Patients with Poor-prognosis Disseminated Nonseminomatous Germ Cell Tumors with Unfavorable Serum Tumor Marker Decline After First Cycle of Chemotherapy. The GCT-SK-003 Phase II Trial
    Mego, Michal
    Rejlekova, Katarina
    Svetlovska, Daniela
    Miskovska, Vera
    Gillis, Ad J. M.
    De Angelis, Valentina
    Kalavska, Katarina
    Obertova, Jana
    Palacka, Patrik
    Reckova, Maria
    Sycova-Mila, Zuzana
    Pindak, Daniel
    Chovanec, Michal
    Looijenga, Leendert H. J.
    Mardiak, Jozef
    EUROPEAN UROLOGY OPEN SCIENCE, 2021, 33 : 19 - 27
  • [4] Extremely high level of tumor markers do not worsen outcome of nonseminomatous germ cell tumors (NSGCT) patients with poor prognosis
    Tryakin, A
    Tjulandin, S
    Titov, D
    Zakharova, T
    Figurin, K
    Feinstein, I
    Garin, A
    ANNALS OF ONCOLOGY, 2005, 16 : 292 - 292
  • [5] Paclitaxel, ifosfamide, and cisplatin (TIP) as salvage and consolidation chemotherapy for advanced germ cell tumor
    Kurobe, Masahiro
    Kawai, Koji
    Oikawa, Takehiro
    Ichioka, Daishi
    Kandori, Shuya
    Takaoka, Ei-ichirou
    Kojima, Takahiro
    Joraku, Akira
    Suetomi, Takahiro
    Miyazaki, Jun
    Nishiyama, Hiroyuki
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2015, 141 (01) : 127 - 133
  • [6] Paclitaxel, ifosfamide, and cisplatin (TIP) as salvage and consolidation chemotherapy for advanced germ cell tumor
    Masahiro Kurobe
    Koji Kawai
    Takehiro Oikawa
    Daishi Ichioka
    Shuya Kandori
    Ei-ichirou Takaoka
    Takahiro Kojima
    Akira Joraku
    Takahiro Suetomi
    Jun Miyazaki
    Hiroyuki Nishiyama
    Journal of Cancer Research and Clinical Oncology, 2015, 141 : 127 - 133
  • [7] Phase II trial of paclitaxel, ifosfamide, and cisplatin (TIP) for previously untreated patients (pts) with intermediate- or poor-risk germ cell tumors (GCT)
    Feldman, Darren Richard
    Hu, James
    Dorff, Tanya B.
    Patil, Sujata
    Van Alstine, Lindsay Joy
    Momen, Lamia
    Carousso, Maryann
    Hughes, Amanda
    Snively-Solomon, Jolie
    Ketchens, Charlean
    Sheinfeld, Joel
    Bains, Manjit S.
    Bajorin, Dean F.
    Bosl, George J.
    Motzer, Robert John
    Quinn, David I.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (06)
  • [8] Adjuvant etoposide plus cisplatin (EP) for pathologic stage (PS) II nonseminomatous germ cell tumor (NSGCT).
    McHugh, Deaglan Joseph
    Funt, Samuel
    Silber, Deborah
    Knezevic, Andrea
    Patil, Sujata
    O'Donnell, Devon
    Tsai, Stephanie
    Reuter, Victor E.
    Sheinfeld, Joel
    Carver, Brett Stewart
    Motzer, Robert J.
    Bajorin, Dean F.
    Bosl, George J.
    Feldman, Darren R.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06)
  • [9] TREATMENT OF POOR RISK NONSEMINOMATOUS GERM-CELL TUMOR (NSGCT) PATIENTS (PTS) WITH CARBOPLATIN(CBDCA)+ETOPOSIDE(E) + BLEOMYCIN (B)
    MOTZER, RJ
    BOSL, GJ
    YAGODA, A
    GOLBEY, R
    PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1987, 28 : 202 - 202
  • [10] Adjuvant etoposide plus cisplatin (EP) for pathologic stage (PS) II nonseminomatous germ cell tumor (NSGCT)
    McHugh, Deaglan Joseph
    Funt, Samuel
    Silber, Deborah
    Knezevic, Andrea
    Patil, Sujata
    O'Donnell, Devon
    Tsai, Stephanie
    Reuter, Victor E.
    Sheinfeld, Joel
    Carver, Brett Stewart
    Motzer, Robert J.
    Bajorin, Dean F.
    Bosl, George J.
    Feldman, Darren R.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
12345